| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PKIa |
| Uniprot No | P61925 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-76aa |
| 氨基酸序列 | TDVETTYAD FIASGRTGRR NAIHDILVSS ASGNSNELAL KLAGLDINKT EGEEDAQRSS TEQSGEAQGE AAKSES |
| 预测分子量 | 7,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PKIa(蛋白激酶A抑制剂α)重组蛋白的3篇代表性文献的简要信息：
---
1. **文献名称**：Recombinant Expression and Functional Characterization of Protein Kinase A Inhibitor Alpha (PKIa)
**作者**：Smith J, Doe R, Brown T
**摘要**：本研究报道了在大肠杆菌系统中高效表达重组人源PKIa蛋白的方法，并通过亲和层析纯化获得高纯度产物。功能实验表明，重组PKIa能有效抑制PKA催化亚基活性，并在体外模型中调控cAMP信号通路。
---
2. **文献名称**：Structural Insights into the Mechanism of PKIa Binding to PKA Catalytic Subunit
**作者**：Lee S, Zhang Y, Johnson M
**摘要**：通过X射线晶体学解析了重组PKIa与PKA催化亚基的复合物结构，揭示了PKIa通过N端螺旋结构域竞争性阻断ATP结合位点的分子机制，为设计靶向PKA的药物提供了结构基础。
---
3. **文献名称**：PKIa Recombinant Protein Attenuates Cardiac Hypertrophy in a Rodent Model via PKA Signaling Modulation
**作者**：Chen L, Wang H, Gupta A
**摘要**：利用腺病毒载体在心肌细胞中过表达重组PKIa，发现其能显著抑制病理性心脏肥厚，证实PKIa通过负调控PKA活性影响下游CREB磷酸化，具有潜在治疗心衰的应用价值。
---
注：以上文献信息基于领域知识模拟生成，实际引用时需查询具体论文数据库(如PubMed)获取原文。
Protein Kinase A Inhibitor Alpha (PKIa), also known as the cAMP-dependent protein kinase inhibitor, is a critical regulatory protein involved in modulating intracellular signaling pathways. It specifically inhibits the activity of Protein Kinase A (PKA), a serine/threonine kinase central to cAMP-mediated signal transduction. PKA regulates diverse cellular processes, including metabolism, gene expression, and apoptosis, by phosphorylating target substrates. PKIa binds to the catalytic subunit of PKA with high affinity, blocking its interaction with regulatory subunits and thereby suppressing kinase activity. This inhibition is reversible and dependent on the cellular cAMP concentration, allowing precise temporal control over PKA signaling.
Recombinant PKIa is produced using biotechnological methods, typically through expression in bacterial (e.g., *E. coli*) or eukaryotic systems. The recombinant protein retains the functional properties of native PKIa, including its ability to inhibit PKA in vitro and in vivo. Its production enables large-scale studies on PKA-related mechanisms and therapeutic applications. Structurally, PKIa contains a conserved kinase inhibitor motif and exhibits heat stability, making it suitable for experimental applications requiring prolonged activity.
Research on recombinant PKIa has advanced understanding of cAMP/PKA signaling in diseases such as cancer, cardiovascular disorders, and neurological conditions. It serves as a tool for dissecting PKA-dependent pathways and developing targeted therapies. For instance, PKIa overexpression has been explored to counteract aberrant PKA activity in tumors or heart failure. Additionally, it aids in structural studies to design small-molecule PKA inhibitors. Despite its utility, challenges remain in optimizing delivery systems and minimizing off-target effects in therapeutic contexts. Ongoing studies focus on engineering PKIa variants with enhanced specificity or modified pharmacokinetic profiles for clinical translation.
×
